The estimated Net Worth of Leaf Ventures Iii, L.P.New ... is at least 21 百万$ dollars as of 11 January 2021. Leaf New owns over 235,294 units of Harpoon Therapeutics stock worth over 21,027,919$ and over the last 6 years Leaf sold HARP stock worth over 0$.
Leaf has made over 2 trades of the Harpoon Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently Leaf bought 235,294 units of HARP stock worth 3,999,998$ on 11 January 2021.
The largest trade Leaf's ever made was buying 428,571 units of Harpoon Therapeutics stock on 12 February 2019 worth over 5,999,994$. On average, Leaf trades about 331,933 units every 350 days since 2019. As of 11 January 2021 Leaf still owns at least 913,860 units of Harpoon Therapeutics stock.
You can see the complete history of Leaf New stock trades at the bottom of the page.
Over the last 6 years, insiders at Harpoon Therapeutics have traded over 62,512,704$ worth of Harpoon Therapeutics stock and bought 26,100,850 units worth 525,945,967$ . The most active insiders traders include & Co., Inc.Merck Sharp & Do...、Ronald Hunt、Bioscience Plc Arix Bioscie.... On average, Harpoon Therapeutics executives and independent directors trade stock every 26 days with the average trade being worth of 9,736,866$. The most recent stock trade was executed by & Co., Inc.Merck Sharp & Do... on 11 March 2024, trading 21,397,205 units of HARP stock currently worth 492,135,715$.
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead tri-specific t-cell activating construct (TriTAC) product candidate is HPN424, which is in Phase I/IIa clinical trials for the treatment of metastatic castration-resistant prostate cancer. It is also developing HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian cancer and other mesothelin-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN328, a product candidate in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate our proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Harpoon Therapeutics executives and other stock owners filed with the SEC include: